Docket No.: GNE.3230R1C149

Page 1 of 1

# July 7, 2005

## Please Direct All Correspondence to Customer Number 30,313

## TRANSMITTAL LETTER INFORMATION DISCLOSURE STATEMENT

Applicant

Goddard et al.

App. No

10/063,718

Filed

JUL 1 1 2005

May 8, 2002

For

SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS

**ENCODING THE SAME** 

Examiner

Sandra L. Wegert

Art Unit

1647

#### CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

neMarie Kaiser, Reg. No.

### Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### Dear Sir:

Enclosed for filing in the above-identified application are:

- An Information Disclosure Statement and PTO/SB/08 equivalent listing references for (X) consideration:
  - (X) Listing 42 references.
  - Enclosing 29 references. (X)
- The Commissioner is hereby authorized to charge any additional fees which may be required, or (X) credit any overpayment, to Account No. 11-1410.
- Return prepaid postcard. (X)

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record

Customer No. 30,313 (619) 235-8550

1804133/jk 070705

JUL 1 1 2005 Applicant

#### INFORMATION DISCLOSURE STATEMENT

Goddard et al.

App. No

10/063,718

Filed

May 8, 2002

SECRETED AND TRANSMEMBRANE

For

POLYPEPTIDES AND NUCLEIC ACIDS

**ENCODING THE SAME** 

Examiner

Sandra L. Wegert

Art Unit

1647

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 42 references to be considered by the Examiner. Also enclosed are 29 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 7 200

AnneMarie Kaiset

Registration No. 37,649

Attoney of Record

Customer No. 30313

(619) 235-8550

Application No.

INFORMATION DISCLOSURE

Filing Date

First Named Inventor

Art Unit

(Multiple sheets used when necessary)

Examiner

SHEET 1 OF 3

	Application No.	10/063,718
	Filing Date	May 8, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1647
	Examiner	Sandra L. Wegert
-	Attorney Docket No.	GNE.3230R1C149

			U.S. PATENT	DOCUMENTS	
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,025,156	02-15-2000	Gwynn, et al.	
	2	6,124,433	09-26-2000	Falb, et al.	
	3	6,156,500	12-05-2000	Falb, Dean	
	4	6,162,604	12-19-2000	Jacob, Chaim O.	
	5	6,228,582	05-08-2001	Rodier, et al.	
	6	6,395,306	05-28-2002	Cui, et al.	
	7	6,414,117	07-02-2002	Levinson, D. A.	
	8	6,465,185	10-15-2002	Goldfine, et al.	
	9	6,498,235	12-24-2002	Sheppard, et al.	
	10	6,562,343	05-13-2003	Levinson, D. A.	
	11	6,645,499	11-11-2003	Lal, et al.	
	12	6,730,502	05-04-2004	Van Hijum, et al.	
	13	6,737,522	05-18-2004	Sundick, et al.	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	14	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 403-404, 453. New York: Garland Publishing.	
	15	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.	
	16	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. <i>Blood</i> , 87(12):5257-5268.	
	17	CHEN, et al. 2002. Discordant Protein and mRNA Expression in Lung Adenocarcinomas. Molecular & Cellular Proteomics 1.4, 304-313.	
	18	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal, Vol. 15, No. 16,</i> pp. 4392-4401.	
	19	GÖKMEN-POLAR, et al., February 2001, Elevated Protein Kinase C βII Is an Early Promotive Event in Colon Carcinogenesis, <i>Cancer Research, Vol. 61</i> , pp.1375-1381.	
	20	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	

Examiner	Signature
----------	-----------

Date Considered

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent 10/063,718 Application No. INFORMATION DISCLOSURE May 8, 2002 Filing Date First Named Inventor STATEMENT BY APPLICANT Goddard, et al. Art Unit 1647 (Multiple sheets used when necessary) Examiner Claire M. Kaufman SHEET 2 OF 3 GNE.3230R1C149 Attorney Docket No.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	21	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. Molecular and Cellular Biology, 1720-1730.	
	22	HANASH, S. 2003. Making sense of microarray data to classify cancer. <i>The Pharmacogenomics Journal</i> , 3:308-311.	
	23	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.	
	24	HANCOCK, W. S. 2004. Do We Have Enough Biomarkers? Journal of Proteome Research, 3(4):685.	
	25	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
	26	HAYNES, et al., 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis, Vol.</i> 19, pp. 1862- 1871.	
	27	HU, et al. 2003. Analysis of Genomic and Proteomic Data Using Advanced Literature Mining. Journal of Proteome Research, Vol. 2, pp. 405-412.	
	28	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns.  Cancer Research, 62:6240-6245.	
	29	JANG A. Hill RP, Sept. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> 15(5): pp. 469-483	
	30	KONOPKA, et al. June 1986. Variable Expression of the Translocated c-abl Oncogene in Philadelphia-Chromosome-Positive B-Lymphoid Cell Lines from Chronic Myelogenous Leukemia Patients, National Academy of Sciences of the United States of America, Vol. 83, No. 11, pp. 4049-4052	
	31	LEWIN, B. 1994. Oncogenes: Gene Expression and Cancer, Chap. 39, pp.1196-1201. Genes V. New York: Oxford University Press.	
	32	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	
	33	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
	34	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	35	OHARA, et al. 2001. Directional cDNA library construction assisted by the in vitro recombination reaction. <i>Nucleic Acids Research, Vol. 29, No e22</i> , pp.1-8.	
	36	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular &amp; Cellular Proteomics</i> , 1:37-45.	
	37	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	

Examiner Signature	Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

8'\
1 2005 년
NFORMATION DISCLOSURE
STATEMENT BY APPLICANT
a Trailie
(Multiple sheets used when necessary)

SHEET 3 OF 3

Application No.	10/063,718	
Filing Date	May 8, 2002	
First Named Inventor	Goddard, et al.	
Art Unit	1647	
Examiner	Claire M. Kaufman	
Attorney Docket No.	GNE.3230R1C149	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	38	POWELL, et al. Oct. 1998. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics, Vol.5:</i> pp. 411-421.	
	39	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol. Annu, 1(27):165-190.	•
	40	VALLEJO, et al. Dec. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. <i>Biochimie</i> 82(12): 1129-33.	
	41	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	
	42	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World Journal of Surgical Oncology, 2:13.	

1802095/jk 070605

- 1	Examiner Signature
-----	--------------------

Date Considered

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.